Table 3.
TGF-β1, active-TGF-β, VEGF-A, and FGF2 in healthy control vs. FD patients in gender-divided groups. Statistical evaluation includes mean ± STEV, t-test, and F-test scores. 95% confidential interval.
| Biomarker | CNT vs. FD | CNT vs. FD Females | CNT vs. FD Males | |||
|---|---|---|---|---|---|---|
| FD | CNT | FD | CNT | FD | CNT | |
| TGFβ1 95% CI |
38.7 ± 4.1 | 12.5 ± 1.4 | 34.7 ± 4.7 | 13.9 ± 1.8 | 43.4 ± 7.1 | 10.9 ± 2.3 |
|
T test p < 0.0001 17.3 to 35 |
T test p < 0.0001 10.4 to 31 |
T test p < 0.0001 16.9 to 47.9 |
||||
| Active TGFβ 95% CI |
148 ± 11 | 111 ± 15 | 125 ± 16 | 81.93 ± 13 | 174 ± 16 | 145 ± 28 |
|
T test p < 0.05 −2.2 to 74.8 |
T test p < 0.05 −1.1 to 87.2 |
T test p = 0.1 |
||||
| VEGF-A 95% CI |
217.3 ± 54.6 | 71.4 ± 9.5 | 163.8 ± 62.4 | 64.7 ± 13.2 | 278.4 ± 92 | 79.6 ± 14 |
|
T test p < 0.005 26.1 to 265.7 |
T test p = 0.11, F test
p < 0.0001 |
T test p < 0.05 −12 to 410 |
||||
| FGF2 95% CI |
90.7 ± 8.9 | 63.3 ± 6.8 | 95.2 ± 15 | 57.3 ± 6.2 | 85.8 ± 8.5 | 69.5 ± 12.9 |
|
T test p < 0.005 4.8 to 50.1 |
T test p < 0.05 3.1 to 72.5 |
F test p = 0.14 |
||||